Fast Five Quiz: Non–Small Cell Lung Cancer Management

Daniel S. Schwartz, MD, MBA


February 03, 2021

For patients with VEGF mutations, VEGF inhibitors may be used in combination with chemotherapy.

An immune checkpoint inhibitor combined with chemotherapy may be an option for patients with high programmed death ligand 1 (PD-L1) expression.

Patients with ALK rearrangements do not benefit from treatment with EGFR-directed TKIs. Instead, first-line therapy may include an ALK-positive inhibitor.

Targeted agents have been developed for patients with NSCLC who have ROS-1 mutations as well.

For additional information, refer to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Non–Small Cell Lung Cancer and the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines: Lung and Chest Tumours.

Learn more about treatment options for NSCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: